Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: Mathematical modeling and experimental verification

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 10, 2013, Pages 2359-2370

  Biondi, Marco ^a,b   Fusco, Sabato ^b   Lewis, Andrew L ^c   Netti, Paolo A ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RELEASE KINETICS; DRUG-RELEASE RATE; EXPERIMENTAL EVALUATION; EXPERIMENTAL VERIFICATION; LANGMUIR ISOTHERM; PHENOMENOLOGICAL MODELS; RATE-CONTROLLING MECHANISM; RELEASE KINETICS;

DRUG PRODUCTS; IONIC STRENGTH; MATHEMATICAL MODELS;

LOADING;

DOXORUBICIN; IRINOTECAN;

ARTICLE; ARTIFICIAL EMBOLISM; BINDING SITE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG ELUTING BEAD; DRUG RELEASE; HYDRODYNAMICS; IONIC STRENGTH; ISOTHERM; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DIFFUSION; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGELS; KINETICS; LIVER NEOPLASMS; MODELS, THEORETICAL; PARTICLE SIZE; TIME FACTORS; WATER;

EID: 84885104590     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-4992-4     Document Type: Article

References (33)

1. Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, Lloyd AW. Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18:1691-9.
2. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A, Kelekis D. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269-80.
3. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45:649-56.
4. Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, Wang AH. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990;29:2538-49.
5. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36:2891-5.
6. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol. 2008;75:1262-71.
7. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-5.
8. Forster RE, Tang Y, Bowyer C, Lloyd AW, Macfarlane W, Phillips GJ, Lewis AL. Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. Anticancer Drugs. 2012;23:355-69.
9. Glage S, Lewis AL, Mertens P, Baltes S, Geigle P, Brinker T. Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate. Clin Transl Oncol. 2012;14:50-9.
10. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387-95.
11. Biondi M, Fusco S, Lewis AL, Netti PA. New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead for use in transarterial chemoembolization (TACE). J Biomater Sci Polym Ed. 2012;23:333-54.
12. Gonzalez MV, Tang V, Phillips GJ, Lloyd AW, Hall B, Stratford PW, Lewis AL. Doxorubicin eluting beads-2: methods for evaluating drug elution and in vitro:in vivo correlation. J Mater Sci Mater Med. 2008;19:767-75.
13. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol. 2006;17:1335-43.
14. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12:2563-7.
15. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30:7-14.
16. Baltes S, Freund I, Lewis AL, Nolte I, Brinker T. Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model. J Mater Sci Mater Med. 2010;21:1393-402.
17. Lewis AL, Holden RR. DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv. 2011;8:153-69.
18. Boudy V, Voute N, Pradeau D, Chaumeil JC. Adsorption of an ionizable drug onto microspheres: experimental and modeling studies. Int J Pharm. 2002;239:13-22.
19. Singh M, Lumpkin JA, Rosenblatt J. Mathematical-modeling of drug-release from hydrogel matrices via a diffusion coupled with desorption mechanism. J Control Release. 1994;32:17-25.
20. Tang Y, Czuczman PR, Chung ST, Lewis AL. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. J Control Release. 2008;127:70-8.
21. Bhaskar R, Murthy RSR, Miglani BD, Viswanathan K. Novel method to evaluate diffusion controlled release of drug from resinate. Int J Pharm. 1986;28:59-66.
22. Boyd GE, Damson AW, Myers LS. The exchange adsorption of ions from aqueous solutions by organic zeolites; kinetics. J Am Chem Soc. 1947;69:2836-48.
23. Abdekhodaie MJ, Wu XY. Drug loading onto ion-exchange microspheres: modeling study and experimental verification. Biomaterials. 2006;27:3652-62.
24. Reichenberg D. Properties of ion-exchange resins in relation to their structure. III. Kinetics of exchange. J Am Chem Soc. 1953;75:589-97.
25. Lustig SR, Peppas NA. Solute diffusion in swollen membranes.9. Scaling laws for solute diffusion in gels. J Appl Polym Sci. 1988;36:735-47.
26. Flynn GL, Yalkowsky SH, Roseman TJ. Mass transport phenomena and models: theoretical concepts. J Pharm Sci. 1974;63:479-510.
27. Kydonieus AF. Treatise on controlled drug delivery: fundamentals, optimization, applications. Colchester: Informa HealthCare; 1992.
28. Cheung RY, Kuba R, Rauth AM, Wu XY. A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres. J Control Release. 2004;100:121-33.
29. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS, Perkins WR. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta. 1998;1415:23-40.
30. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol. 2010;21:1084-90.
31. Dicko A, Tardi P, Xie X, Mayer L. Role of copper gluconate/ triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm. 2007;337:219-28.
32. Nabiev I, Fleury F, Kudelina I, Pommier Y, Charton F, Riou JF, Alix AJ, Manfait M. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem Pharmacol. 1998;55:1163-74.
33. Pauly S. Permeability and diffusion data. In: Brandrup J, Immergut EH, editors. Polymer Handbook. 3rd ed. Chichester: Wiley-Interscience; 1989.